RxDoctor Payments Data

Timothy Kearins

Optometrist · Portland, MENPI 1093908816

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Coopervision Inc. at 40.5% of the total.

$871in general payments, 2019–2025

Across 24 payments — averaging $36.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$353
  • Alcon$236
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$146
  • Sun Pharmaceutical Industries Inc.$56
  • Novartis$33
  • Bausch & Lomb Americas Inc.$30
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$871 in reported general payments places this provider in the 75th percentile of 224 optometrist providers in Maine.

See all optometrist providers in Maine

Medicare billing

Part B allowed, 2024
$84,926
Medicare patients
481
Services billed
2,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$33,616
LumiganBimatoprost42$19,773
CombiganBrimonidine Tartrate/Timolol14$3,020
Timolol Maleate139$2,069
Latanoprost158$2,011
Brinzolamide13$1,819
Tobramycin-DexamethasoneTobramycin/Dexamethasone30$1,129
Brimonidine Tartrate15$1,071
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$465
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha49$429
Dorzolamide Hcl25$355

Paid to pharmacies, not to this prescriber.

Other optometrist in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →